Sevda Bayramova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sevda Bayramova has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Romanov
Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени академика Е.Н. Мешалкина» Министерства здравоохранения Российской Федерации
5 shared publications - Evgeny Pokushalov
Scientific Research Laboratory, Triangel Scientific, San Francisco, CA 94101, USA
5 shared publications - Denis Losik
LLC MedicBook
3 shared publications - A. A. Aleksandrovskiy
Ogarev State Medical University
2 shared publications - A. Yu. Dmitriev
Kraevaya Clinical Hospital
2 shared publications - Alexander Karaskov
E. N. Meshalkin National Medical Research Center of the Ministry of Health
2 shared publications
Latest Publications
- Open Access
- 8 June 2020
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 25 (5) , 3874
Antiarrhythmic drug therapy after atrial fibrillation ablation: data of the ESC-EHRA registry
Aim. Catheter ablation (CA) is an effective approach for rhythm control in atrial fibrillation (AF), however antiarrhythmic therapy (AAT) remains important. There is a lack of data about long-term AAT use after CA. This study evaluates AAT after CA for AF.Material and methods. In 2012-2016, EURObservational Research Programme of Atrial Fibrillation Ablation Long-Term (EORP AFA L-T) registry was conducted, which included 476 Russian patients (57,1% — men; mean age — 57,1±8,7 years). The follow-up after CA was 12 months (available in 81,9% of patients). The use of AAT was evaluated prior to hospitalization, during hospitalization for CA, as well as at 3, 6 and 12 months of follow-up.Results. Prior to CA, 439 (92,2%) patients received AAT During CA, 459 (96,4%) patients were treated with AAT. After CA, AAT was used by 463 (97,3%), 370 (94,8%), and 307 (78,7%) patients at 3, 6 and 12 months of follow-up, respectively. There was no arrhythmia recurrence in 187 (47,9%) subjects. Among these patients, 40 (21,4%) received class IC or III AAT. The peak of AAT use was found for class IC agents within 3 months after CA (PConclusion. The frequency of AAT use after AF ablation is significantly reduced. However, there is a cohort of patients without documented arrhythmia recurrence still receiving AAT, which requires special attention of physicians. There were no clinical predictors of continued AAT in subjects without arrhythmia recurrence.
- 8 June 2020
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 25 (5) , 3874
Open AccessAntiarrhythmic drug therapy after atrial fibrillation ablation: data of the ESC-EHRA registry
Aim. Catheter ablation (CA) is an effective approach for rhythm control in atrial fibrillation (AF), however antiarrhythmic therapy (AAT) remains important. There is a lack of data about long-term AAT use after CA. This study evaluates AAT after CA for AF.Material and methods. In 2012-2016, EURObservational Research Programme of Atrial Fibrillation Ablation Long-Term (EORP AFA L-T) registry was conducted, which included 476 Russian patients (57,1% — men; mean age — 57,1±8,7 years). The follow-up after CA was 12 months (available in 81,9% of patients). The use of AAT was evaluated prior to hospitalization, during hospitalization for CA, as well as at 3, 6 and 12 months of follow-up.Results. Prior to CA, 439 (92,2%) patients received AAT During CA, 459 (96,4%) patients were treated with AAT. After CA, AAT was used by 463 (97,3%), 370 (94,8%), and 307 (78,7%) patients at 3, 6 and 12 months of follow-up, respectively. There was no arrhythmia recurrence in 187 (47,9%) subjects. Among these patients, 40 (21,4%) received class IC or III AAT. The peak of AAT use was found for class IC agents within 3 months after CA (PConclusion. The frequency of AAT use after AF ablation is significantly reduced. However, there is a cohort of patients without documented arrhythmia recurrence still receiving AAT, which requires special attention of physicians. There were no clinical predictors of continued AAT in subjects without arrhythmia recurrence.
- Open Access
- 14 August 2018
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- No. 7,p. 7-15
CLINICAL CHRACTERISTICS OF PATIENTS AND RESULTS OF CATHETER ABLATION IN ATRIAL FIBRILLATION IN RUSSIA: SUBANALYSIS OF THE EUROPEAN REGISTRY 2012-2016
Aim. The results presented, of subanalysis of the catheter ablation (CA) registry in atrial fibrillation (AF) with the patients properties, specifics of CA and treatment results, in Russia comparing to European countries.Material and methods. During 2012 to 2015, totally 3742 patients included to the registry, of those 477 in Russia. In 467 Russian patients (males 56,5%; mean age 58,5 y. o.) CA AF was done. During one year 392 patients were followed up. Minimum requirements to follow-up: routine ECG registration and non less than one contact after 12 months passed.Results. In Russian patients there were more common obesity (46,1% and 29,2%, pConclusion. In real clinical setting, high efficacy of CA AF was shown, resistant to antiarrhythmic therapy. In most of Russian patients there were cardiovascular comorbidities. There was lower rate of reported adverse events in Russian centers of interventional treatments.
- 14 August 2018
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- No. 7,p. 7-15
Open AccessCLINICAL CHRACTERISTICS OF PATIENTS AND RESULTS OF CATHETER ABLATION IN ATRIAL FIBRILLATION IN RUSSIA: SUBANALYSIS OF THE EUROPEAN REGISTRY 2012-2016
Aim. The results presented, of subanalysis of the catheter ablation (CA) registry in atrial fibrillation (AF) with the patients properties, specifics of CA and treatment results, in Russia comparing to European countries.Material and methods. During 2012 to 2015, totally 3742 patients included to the registry, of those 477 in Russia. In 467 Russian patients (males 56,5%; mean age 58,5 y. o.) CA AF was done. During one year 392 patients were followed up. Minimum requirements to follow-up: routine ECG registration and non less than one contact after 12 months passed.Results. In Russian patients there were more common obesity (46,1% and 29,2%, pConclusion. In real clinical setting, high efficacy of CA AF was shown, resistant to antiarrhythmic therapy. In most of Russian patients there were cardiovascular comorbidities. There was lower rate of reported adverse events in Russian centers of interventional treatments.
- 1 September 2014
- Published by Elsevier in Heart Rhythm
- Vol. 11 (9) , 1567-1572
Prophylactic pulmonary vein isolation during isthmus ablation for atrial flutter: The PReVENT AF Study I
- 1 September 2014
- Published by Elsevier in Heart Rhythm
- Vol. 11 (9) , 1567-1572
Prophylactic pulmonary vein isolation during isthmus ablation for atrial flutter: The PReVENT AF Study I